Braveheart Bio, Inc. BRVE
20.90 USD +1.28 (+6.52%)
At closeNov 11, 2026, 4:26 PM EST
20.90 0.00 0.00%
After hours · Nov 11, 4:26 PM ET
19.41 Day range 21.85
16.70 52-week range 32.00
- YTD
- -29.87%
- 1 year
- -29.87%
- Market cap
- 1.88B
- EPS (ttm)
- -6.08
- Shares out
- 90.04M
- Forward P/E
- -10.50
- YTD return
- -29.87%
- 1-year return
- -29.87%
- Volume
- 488.97K
- Avg volume
- 448.07K
- Open
- 20.04
- Previous close
- 19.62
- Day's range
- 19.41 – 21.85
- 52-week range
- 16.70 – 32.00
- Analysts
- Strong Buy
- Price target
- 45.25 (+116.5%)
- Earnings date
- Dec 8, 2026
5D -1.92 (-8.91%)
Key statistics
- Enterprise value
- 1.69B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 122.83M
- Total debt
- 575.00K
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 22.45
- 200-day average
- 23.76
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 45.25 +116.5% upside
Now 20.90
- Target (low)
- 40.00
- Target (mean)
- 45.25
- Target (high)
- 48.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy0
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Dec 8, 2026
Expected Dec 8, 2026. Consensus EPS estimate 0.00.
Financials — quick view
BRVE Revenue — quarterly 0
BRVE Net income — quarterly -14.99M
BRVE EPS — quarterly -2.51
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 8, 2026 | Sep 30, 2026 | -0.438 | — | — | — |
| Sep 8, 2026 | Jun 30, 2026 | 2.69 | -2.51 | -5.20 | -193.31% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 20, 2026 | Cantor Fitzgerald | reit | Overweight | Overweight |
About Braveheart Bio, Inc.
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- braveheart.bio
News
Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update 
Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in London 
Braveheart Bio, Inc. (BRVE) Shareholder/Analyst Call Transcript 
Braveheart Bio Shares One-Year Heart Drug Data, Plans New Fixed-Dose Trial 
Hengrui Pharma And Braveheart Bio Report Durable 52-Week HRS/BHB-1893 Benefits In oHCM; Says Data Across Both Forms Of HCM And Preclinical Models Suggest Potential To Address Underlying Pathophysiology Of Disease, Findings Consistent With Reverse-remodeling And Diastolic Benefits; To Host Investor Event And Webcast Today At 4:35 p.m. ET 
Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026 
Braveheart Bio Announces Late-breaking Presentation Of 52-Week Extension Data For BHB-1893 In Obstructive HCM At The American Heart Association Scientific Sessions, November 6-9; Will Also Host Webinar - Cantor Fitzgerald Reiterates Overweight on Braveheart Bio, Maintains $40 Price Target
- Braveheart Bio Q2 EPS $(2.51)
This Airbnb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Your note
Sign in to keep a note on BRVE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHIMOVITS EREZ | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 6, 2026 | 0 |
| JIANGSU HENGRUI PHARMACEUTICALS CO. LTD. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Aug 6, 2026 | 7,420,090 |
| LUBNER DAVID CHARLES | Director | Purchase | Aug 6, 2026 | 55,555 |
| MURDOCH TRAVIS | Chief Executive Officer | Purchase | Aug 6, 2026 | 8,333,640 |
| RICKEY JAMES PAUL | Chief Financial Officer | Purchase | Aug 6, 2026 | 703,575 |
| VIEHBACHER CHRISTOPHER | Director | Purchase | Aug 6, 2026 | 759,857 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 8.42% | 7,585,769 | 158.54M | Sep 29, 2026 |
| Geode Capital Management, LLC | 0.32% | 288,798 | 6.04M | Sep 29, 2026 |
| UBS Group AG | 0.25% | 229,072 | 4.79M | Sep 29, 2026 |
| Leonard Rickey Investment Advisors P.L.L.C. | 0.04% | 36,109 | 754.68K | Sep 29, 2026 |
| Squarepoint Ops LLC | 0.04% | 40,282 | 841.89K | Sep 29, 2026 |
| SBI Securities Co., Ltd. | 0.00% | 10 | 208 | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 2.52% | 2,273,151 | 47.51M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.15% | 1,035,862 | 21.65M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.87% | 779,600 | 16.29M | Sep 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 0.80% | 718,200 | 15.01M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 0.62% | 559,564 | 11.69M | Sep 29, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 0.56% | 500,000 | 10.45M | Sep 29, 2026 |